• Results from the at-home test kit are available to HCPs and their patients through 1health

LOS ANGELES / Jul 23, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, launches the Niagen+ NAD+ Test Kit*, now available exclusively through the company’s healthcare practitioner (HCP) channel. This innovative test kit provides practitioners with a reliable method for measuring patient blood NAD+ levels, helping them create more personalized and effective patient protocols using ChromaDex’s NAD+-boosting HCP products, Tru Niagen^® and Niagen+.

Tru Niagen is a suite of oral dietary supplements featuring Niagen (patented nicotinamide riboside or NR), the most efficient and high-quality NAD+ precursor available. Niagen+ features pharmaceutical-grade Niagen (patented nicotinamide riboside chloride or NRC) and will soon be available as Niagen IV and injections exclusively at clinics from U.S. FDA 503B-registered outsourcing facilities with a prescription. Representing a significant advancement in intravenous NAD+ therapy, practitioners are eager to provide Niagen IV therapy to patients.

Rob Fried, CEO of ChromaDex and Founder of Tru Niagen, noted, "Our healthcare practitioners have requested a tool to measure blood NAD+ levels, and we believe this is the best product now available on the market."

Setting a new standard in analytical NAD+ measurement methods, the Niagen+ NAD+ Test Kit features cutting-edge dried blood spot (DBS) assay technology, ensuring the stability of NAD+ samples during transport for precise and accurate results. Other test kits use a less reliable DBS card, which requires adding a fixer solution to stabilize NAD+, which often degrades during the DBS drying process. With this innovative Niagen+ NAD+ test, HCPs can provide patients with personalized and effective protocols by more accurately tracking NAD+ changes over time.

Key Niagen+ NAD+ Test Kit features

• Innovative test card technology: A unique blood spot test card maintains the stability of NAD+ throughout the transport process and ensures accurate measurement.
• Baseline and progress tracking: While each HCP will determine the patient protocol, the test can be used to understand NAD+ levels before Tru Niagen NAD+-boosting and/or Niagen IV and injections to establish a baseline and again after NAD+ boosting therapy to track changes.
• Validated, trusted results: Analyses are conducted at a Clinical Laboratory Improvement Amendments (CLIA) and the College of American Pathologists (CAP) accredited clinical genomics and biochemical testing laboratory with expertise in mass spec-based assays.
• Precision analysis: NAD+ measurements are conducted on the blood sample affixed to the DBS card using the gold standard analytical method, high-resolution liquid chromatography/tandem mass spectrometry (LC-MS/MS).

How it works

HCPs will provide patients with an at-home Niagen+ NAD+ Test Kit, which patients will register on the 1health platform. Once registered, the patient will follow the instructions within the kit to procure a sample with the DBS card and send it to the lab using a prepaid envelope. Results will be available to both patients and doctors in about two weeks through 1health.

Mehdi Maghsoodnia, CEO at 1health, emphasized the critical role of 1health’s platform in the successful launch of the Niagen+ NAD+ Test Kit. “We are proud to partner with ChromaDex to bring this innovative testing solution to healthcare practitioners. Our robust software seamlessly integrates with both the warehouse and the lab, ensuring efficient fulfillment of kits and accurate delivery of results. This collaboration provides invaluable insights for practitioners aiming to optimize their patients' NAD+ levels, enabling personalized and effective NAD+ boosting protocols, such as Tru Niagen oral supplementation and soon Niagen IV and injection, to maximize therapeutic outcomes.”

Practitioners can learn more about the test kit, view all HCP products, and find research on clinical practice applications at www.truniagenpro.com. To learn more about ChromaDex, please visit www.chromadex.com.

*This product is not intended to diagnose, prevent, or treat a condition. Measurements and statistics are intended for informational and educational purposes only, to support general health and wellness. This product has not been tested with individuals with health conditions and has not been cleared or approved by the U.S. Food and Drug Administration.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to the Niagen+ NAD+ Test Kit, now available exclusively through the company’s healthcare practitioner (HCP) channel. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

About ChromaDex

ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality.

Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.

Niagen^® is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen^®, the number one healthy-aging NAD+ supplement in the United States^†. Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at www.truniagen.com).

ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, where copies of press releases, news, and financial information are regularly published.

^†Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).